WAVE Life Sciences Ltd.

WVE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 73.9%, EPS fell 9.68% and free cash flow fell 17.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.12 0.07 −2.19%
Market cap
$628.6M
P/E
0.0×
Fwd P/E
−6.2×
Dividend yield
—
F-score
3/9
Altman Z
11.34
Beneish M
−2.44
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
18.13 20.21 67.10 11.24
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(22.12) (24.37) (84.88) (27.49)
P/B ratio
2.61 2.84 5.53 9.86
EV/Sales
10.63 12.63 53.01 9.44
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(3.60) (4.90) (12.03) (5.21)
Current Ratio
9.99 11.26 6.47 2.51
Net Debt/EBITDA
6.87 18.78 11.11 3.63
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(18.76%) (14.62%) (7.18%) (10.11%)
Free Cash Flow Yield
(16.30%) (12.75%) (6.56%) (16.14%)
Free Cash Flow per Share
(0.27) (0.30) (0.20) (0.27)
Book value per Share
2.22 2.56 3.07 0.74
Free Cash Flow
(54.47) (59.99) (33.77) (44.91)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates